 |
Medivation Announces Third Quarter Financial Results Teleconference and Webcast on November 9, 2011
Nov 2, 2011
|
7.8 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/02/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter financial results and provide a general business update on Wednesday, November 9, 2011 at 4:30 p.m. Eastern Time. A press release for the third quarter ended o...
|
|
Medivation Announces Participation at Two Upcoming Investor Conferences
Sep 23, 2011
|
8.0 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 09/23/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following two investor conferences:
The JMP Securities Healthcare Conference on September 27 at 1:30pm Eastern Time at the St. Regis Hotel in New York...
|
|
Medivation Names Cheryl Cohen Chief Commercial Officer
Sep 8, 2011
|
11.3 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 09/08/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced the appointment of Cheryl Cohen as chief commercial officer. In this position, Ms. Cohen will lead the sales and marketing functions, reporting to David Hung, M.D., president and chief executive officer of Medivation.
"As we approac...
|
|
Medivation Announces Participation at Two Upcoming Investor Conferences
Sep 6, 2011
|
8.1 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 09/06/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will participate at the following two investor conferences:
Panel discussion titled "Finally Lots of Options in Treating Prostate Cancer" at Citi's 6th Annual Biotech Day...
|
|
Medivation Reports Second Quarter 2011 Financial Results and Provides Corporate Update
Aug 9, 2011
|
21.4 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 08/09/11 --
Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the second quarter ended June 30, 2011.
"We and our partner Astellas continue to work diligently toward our goal of developing MDV3100 across the spectrum of advanced prostate...
|
|
Medivation and Astellas Announce New Preclinical Study Results Showing MDV3100 Blocks Breast Cancer Cell Growth
Aug 4, 2011
|
13.9 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 08/04/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced results from a preclinical study conducted by researchers at the University of Colorado Denver that provide evidence that MDV3100 inhibits proliferation of breast cancer cells. In different cell-based assays, MDV...
|
|
Medivation Announces Second Quarter Financial Results Teleconference and Webcast on August 9, 2011
Aug 2, 2011
|
7.6 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 08/02/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter financial results and provide a general business update on Tuesday, August 9, 2011 at 4:30 p.m. Eastern Time. A press release for the second quarter ended on ...
|
|
Medivation Names Stewart Hallett Vice President of Clinical Operations
Jul 13, 2011
|
7.8 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 07/13/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that Stewart Hallett, MBA, has been promoted to vice president, clinical operations. He takes the position with nearly 20 years of biopharmaceutical and healthcare industry experience and 16 years of direct experience in clinical research and deve...
|
|
Medivation and Astellas Announce New Study Results Confirming Clinical Effects and Tolerability of MDV3100 in Advanced Prostate Cancer
Jun 4, 2011
|
13.1 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 06/04/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced preliminary results from an ongoing study conducted at MD Anderson Cancer Center that provides additional evidence of the clinical effects and tolerability of MDV3100 in patients with advanced prostate cancer. MD...
|
|
Medivation Announces Webcast of MDV3100 Investor Briefing at ASCO and Corporate Presentation at Jefferies Global Healthcare Conference
May 26, 2011
|
8.3 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 05/26/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold the following events in June:
David Hung, Medivation's president and chief executive officer, Lynn Seely, Medivation's chief medical officer, and key opinion leaders Howard I. Scher, M.D., and Neal D. Shore, M.D., ...
|
|
Medivation and Astellas Announce Upcoming Presentation of MDV3100 Data at the American Society of Clinical Oncology Annual Meeting
May 19, 2011
|
10.9 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 05/19/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that data from a study conducted at MD Anderson Cancer Center evaluating the investigational drug MDV3100, a triple-acting oral androgen receptor antagonist, will be presented in an oral session at the upcoming A...
|
|
Medivation and Astellas Announce Upcoming Presentation of Long-Term Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
May 12, 2011
|
11.0 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 05/12/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that long-term efficacy data from the Phase 1-2 trial of MDV3100, a triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer will be presented in an oral session at the American ...
|
|
Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients
May 9, 2011
|
13.9 KB |
|
| |
TOKYO and SAN FRANCISCO, CA -- (MARKET WIRE) -- 05/09/11 --
Astellas Pharma Inc. and Medivation, Inc. (NASDAQ: MDVN) today announced treatment of the first patient in the second new Phase 2 clinical trial of the investigational drug MDV3100, a triple-acting oral androgen receptor antagonist. This trial is evaluating MDV3100 monotherapy as the ...
|
|
Medivation Reports First Quarter 2011 Financial Results and Provides Corporate Update
May 6, 2011
|
18.8 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 05/06/11 --
Medivation, Inc. (NASDAQ: MDVN) today
provided a corporate update and reported its financial results for the
first quarter ended March 31, 2011.
"We and our partner Astellas continue to make substantial progress with our
MDV3100 program. We now have multiple MDV3100 trial...
|
|
Medivation Names Gretchen Burke Vice President of Finance and Business Processes
May 3, 2011
|
7.8 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 05/03/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that Gretchen Burke, an executive with more than 25 years of finance and business experience, has joined the company as vice president, finance and business processes.
"We are delighted to welcome a finance officer of Gretchen's cal...
|
|
Medivation Announces Upcoming Teleconference, Webcasts and Conference Participation
Apr 29, 2011
|
8.6 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 04/29/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold the following events in May:
A teleconference and webcast with management to discuss first quarter 2011 financial results and provide a general business update on Friday, May 6, 2011 at 4:30 p.m. Eastern Time. A pr...
|
|
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Apr 11, 2011
|
14.2 KB |
|
| |
NEW YORK, NY and SAN FRANCISCO, CA -- (MARKET WIRE) -- 04/11/11 --
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-prima...
|
|
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Monday, April 11 to Discuss Phase 3 Trial Results for Dimebon in Huntington Disease
Apr 8, 2011
|
7.8 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 04/08/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time, Monday, April 11, to discuss the HORIZON Phase 3 trial results for dimebon (latrepirdine) in patients with Huntington disease. A press release will be issued at 7:30 a.m. Ea...
|
|
Medivation Announces Participation in Leerink Swann Cancer Roundtable Conference
Mar 31, 2011
|
7.7 KB |
|
| |
SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/31/11 --
Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Cancer Roundtable Conference on Thursday, April 7, at 11:40 a.m. Eastern Time and participate in a panel discussion on prostate cancer at 12:15 p.m. Ea...
|
|
Medivation and Astellas Announce Initiation of Phase 2 Clinical Trial Comparing MDV3100 With Bicalutamide in Advanced Prostate Cancer
Mar 30, 2011
|
13.7 KB |
|
| |
SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 03/30/11 --
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced treatment of the first patient in the TERRAIN study, a Phase 2 comparison of the investigational drug MDV3100, a triple-acting oral androgen receptor antagonist, with bicalutamide, a commonly used anti-androgen, ...
|
|
|